Nam Chol Park

Clinical-stage spinout with proprietary cancer immunotherapy platform, offering off-the-shelf therapy with no HLA restrictions, strong safety, high immunogenicity and cost-effective manufacturing. Strong P1 results in NSCLC, ovarian, and prostate cancers.